Compare
Jaguar Health, Inc. vs Prelude Therapeutics Inc vs Emmaus Life Sciences, Inc. vs Evommune, Inc.
| Latest fiscal year | Jaguar Health, Inc. JAGX | Prelude Therapeutics Inc PRLD | Emmaus Life Sciences, Inc. EMMA | Evommune, Inc. EVMN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.51M | $12.14M | $12.45M | $13.00M |
| Revenue growth (YoY) | -1.5% | +73.4% | -25.2% | +85.7% |
| Gross margin | 67.2% (computed) | n/a | 93.1% | n/a |
| Operating margin | -398.8% | -861.3% | 1.9% | -623.6% |
| Net margin | -465.4% | -819.6% | -60.2% | -529.8% |
| Net income | -$53.58M | -$99.50M | -$7.49M | -$68.87M |
| EPS (Diluted) | -$22.97 | -$1.29 | -$0.12 | -$11.22 |
| Operating cash flow | -$23.69M | -$56.30M | -$11.0K | -$76.44M |
| Free cash flow | n/a | -$56.37M | -$12.0K | -$76.68M |
| Cash & equivalents | $968.0K | $35.26M | $2.13M | $44.06M |
| Total assets | $38.32M | $141.31M | $21.44M | $224.95M |
| Total liabilities | $57.01M | $72.68M | $85.04M | $19.38M |
| Shareholders' equity | -$18.69M | $68.64M | -$63.61M | $205.57M |
| Return on year-end equity | n/a | -145.0% | n/a | -33.5% |
| Shares outstanding | n/a | n/a | 70.19M | 31.52M |
Revenue, most recent five fiscal years
| Fiscal year | Jaguar Health, Inc. | Prelude Therapeutics Inc | Emmaus Life Sciences, Inc. | Evommune, Inc. |
|---|---|---|---|---|
| Latest | $11.51M Ended 2025-12-31 | $12.14M Ended 2025-12-31 | $12.45M Ended 2025-12-31 | $13.00M Ended 2025-12-31 |
| 1 year earlier | $11.69M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $16.65M Ended 2024-12-31 | $7.00M Ended 2024-12-31 |
| 2 years earlier | $9.76M Ended 2023-12-31 | n/a | $29.60M Ended 2023-12-31 | n/a |
| 3 years earlier | $11.96M Ended 2022-12-31 | n/a | $18.39M Ended 2022-12-31 | n/a |
| 4 years earlier | $4.33M Ended 2021-12-31 | n/a | $20.61M Ended 2021-12-31 | n/a |